1992
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
Guttman M, Léger G, Cedarbaum J, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals Of Neurology 1992, 31: 638-643. PMID: 1514775, DOI: 10.1002/ana.410310611.Peer-Reviewed Original ResearchConceptsChronic L-DOPA therapyAdvanced Parkinson's diseaseL-dopa therapyPositron emission tomographic studiesL-DOPA administrationEmission tomographic studiesPositron emission tomographyL-dopa preparationsParkinsonian patientsPlasma concentrationsCynomolgus monkeysParkinson's diseasePatientsEmission tomographyL-DOPABrainTomographic studiesDiseaseAdministrationInfusionTherapyBlood
1991
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease.
Cedarbaum J, Leger G, Guttman M. Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease. Clinical Neuropharmacology 1991, 14: 330. PMID: 1913700, DOI: 10.1097/00002826-199108000-00005.Peer-Reviewed Original Research
1990
Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys.
Cedarbaum JM, Léger G, Reches A, Guttman M. Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys. Clinical Neuropharmacology 1990, 13: 544. PMID: 2276119, DOI: 10.1097/00002826-199012000-00006.Peer-Reviewed Original ResearchConceptsCynomolgus monkeysEffect of nitecaponePeripheral COMT inhibitorSingle-dose studyPharmacokinetics of levodopaBlood-brain barrierConcentration-time curveLevodopa administrationPlasma pharmacokineticsCOMT inhibitorsAdverse physiological effectsFurther inhibitionLevodopaDoseNitecaponePhysiological effectsMonkeysPharmacokineticsNovel inhibitorsInhibitorsInhibitionCarbidopaAdministration
1989
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989, 39: 38-44; discussion 59. PMID: 2586762.Peer-Reviewed Original ResearchConceptsSinemet CRLevodopa levelsNew controlled-release formulationStandard Sinemet 25/100Advanced Parkinson's diseasePlasma levodopa levelsBioavailability of levodopaClinical observation studyAntiparkinsonian effectsLevodopa intakeSinemet 25/100Standard SinemetPharmacodynamic comparisonMedication dosesInterdose intervalParkinson's diseaseCR preparationControlled-release formulationLevodopaMotor performanceCarbidopaObservation studyDiseaseProlongationSinemet
1988
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Cedarbaum J, Kutt H, McDowell F. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988, 38: 533-6. PMID: 3352906, DOI: 10.1212/wnl.38.4.533.Peer-Reviewed Original ResearchConceptsDaily intakeRecent clinical trialsMean daily intakeTotal daily intakeLevodopa intakeStandard SinemetClinical responseLevodopa preparationsBrain uptakeClinical trialsPlasma concentrationsClinical significanceBlood samplingLevodopaTherapeutic efficacyMethyldopa levelsControlled-release formulationPatientsIntakeTime curveAUCSinemetLevelsTrials